Laryngeal tuberculosis

Summary

Laryngeal tuberculosis (MONDO:0005819) is a disease. A subtype of extrapulmonary tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	laryngeal tuberculosis
Mondo ID	MONDO:0005819
EFO	EFO:0007337
MeSH	D014387
DOID	DOID:1583
NCIT	C26895
SNOMED CT	70341005
UMLS	C0041315
MedGen	11945
GARD	0024235
Anatomy (UBERON)	UBERON:0001737
Is cancer (heuristic)	no

Also known as: larynx tuberculosis · tuberculous laryngitis

Disease family

This is a subtype of extrapulmonary tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › extrapulmonary tuberculosis › laryngeal tuberculosis

Related subtypes (12): abdominal tuberculosis, cardiac tuberculosis, central nervous system tuberculosis, gastrointestinal tuberculosis, lymph node tuberculosis, miliary tuberculosis, pericardial tuberculosis, pleural tuberculosis, skeletal tuberculosis, urogenital tuberculosis, ocular tuberculosis, cutaneous tuberculosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.